Cetirizine

證據等級: L5

預測適應症: 6 個

Cetirizine: From Allergic Rhinitis to Allergic Urticaria

One-Sentence Summary

Cetirizine is a second-generation, selective histamine H1-receptor antagonist widely used globally for allergic rhinitis and urticaria. The TxGNN model predicts it may be effective for Allergic Urticaria, with 3 clinical trials and 18 publications currently supporting this direction. While this indication is well-established internationally, Cetirizine currently has no Philippines regulatory registration, making formal market entry the primary next step.

Quick Overview

Item	Content
Original Indication	Allergic rhinitis / chronic urticaria (globally recognized; no Philippines regulatory record available)
Predicted New Indication	Allergic Urticaria
TxGNN Prediction Score	99.99%
Evidence Level	L2
Philippines Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from the Evidence Pack. Based on known pharmacological information, Cetirizine is a selective histamine H1-receptor antagonist and the carboxylated metabolite of hydroxyzine. It competitively blocks peripheral H1 receptors with minimal central nervous system penetration — a key advantage over first-generation antihistamines. Beyond simple receptor blockade, Cetirizine also inhibits eosinophil chemotaxis during the late-phase allergic response, giving it an additional anti-inflammatory dimension that enhances its utility in allergic skin diseases.

Allergic urticaria is primarily driven by IgE-triggered mast cell degranulation, which floods the dermis with histamine, triggering vasodilation and increased vascular permeability — the classic wheal-and-flare reaction. Because H1-receptor activation is the central step in this cascade, the mechanistic link between Cetirizine and allergic urticaria is exceptionally direct. This is not a speculative extrapolation; it is the textbook pharmacological rationale upon which the entire second-generation antihistamine class was developed.

The TxGNN model assigns this prediction a near-perfect score (99.99%), reflecting the strength of this mechanistic relationship in the knowledge graph. US FDA and EMA have already approved Cetirizine for urticaria globally. The Evidence Level is rated L2 rather than L1 because the only identified Phase 3 trial in this pack (NCT02023164) was a feasibility pilot with only 36 patients — designed to test whether a definitive Phase 3 was feasible, not to provide confirmatory efficacy data. The weight of global regulatory approval and published literature nonetheless strongly supports clinical validity.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02023164	Phase 3	Completed	36	Multicenter parallel-group pilot RCT comparing IV Cetirizine 10 mg vs. IV Diphenhydramine 50 mg for acute urticaria in emergency departments and urgent care settings; primary purpose was to establish feasibility for a subsequent definitive Phase 3 trial, with preliminary safety and efficacy signals
NCT03296358	N/A	Completed	75	Randomized double-blind trial evaluating short-burst corticosteroid added to standard H1 antihistamine treatment for urticaria; indirectly supports H1 antihistamines (the likely backbone comparator) as the established first-line standard of care
NCT01008592	N/A	Terminated	11	Investigated the effect of levocetirizine — the active R-enantiomer of cetirizine — on skin inflammatory mediators (histamine, prostaglandin E2, LTB4, cathepsins) in symptomatic dermatographism and chronic idiopathic urticaria; terminated early, providing partial mechanistic data

Literature Evidence

PMID	Year	Type	Journal	Key Findings
33030434	2021	Systematic Review	J Investig Allergol Clin Immunol	Critically reviewed evidence for up-dosing second-generation oral antihistamines (including cetirizine) to 4× the licensed dose in chronic spontaneous urticaria; confirms antihistamines as first-line standard, though high-dose evidence relies mainly on expert opinion
7645679	1995	Clinical Trial Series	Allergy	Clinical studies with cetirizine specifically in allergic rhinitis and chronic urticaria; provides direct evidence of cetirizine efficacy in urticarial conditions
1981354	1990	Comprehensive Drug Review	Drugs	Foundational comprehensive review of cetirizine pharmacology; confirms efficacy in chronic urticaria, absence of CNS depression at standard 10 mg dose, and additional anti-inflammatory effects including inhibition of eosinophil chemotaxis
7510611	1993	Drug Review	Drugs	Reappraisal of cetirizine pharmacological properties; confirms effective and well-tolerated treatment for chronic idiopathic urticaria in adults at 10 mg/day
8477125	1993	Drug Review	Ann Pharmacother	Introduction of cetirizine as a nonsedating antihistamine; covers mechanism of action, comparative clinical trials, and adverse effect profile
9951950	1999	Comparative Review	Drugs	Head-to-head comparative review of ten second-generation antihistamines including cetirizine; evaluates sedation, anticholinergic effects, and clinical choice factors for urticaria and allergic rhinitis
41602253	2025	Case Report	Cureus	Case of rebound pruritus and urticaria following cetirizine discontinuation after long-term use in an Asian patient; highlights a clinically relevant safety signal for chronic urticaria management in the Asian population
27110120	2016	Review	Ther Clin Risk Manag	Reviews antihistamine treatment landscape for allergic rhinitis and urticaria; positions cetirizine as an established reference comparator within the second-generation antihistamine class
35593100	2022	Systematic Review	Am J Rhinol Allergy	Systematic review and meta-analysis of RCTs evaluating antihistamines for allergic rhinitis and chronic urticaria; provides class-level quantitative evidence supporting H1 antagonism as the mechanistic basis for urticaria management
18336052	2008	PK/Comparative Review	Clin Pharmacokinet	Comparative pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine, and levocetirizine (cetirizine’s active enantiomer); provides mechanistic context and PK rationale for the cetirizine class in chronic urticaria

Philippines Market Information

Cetirizine currently has no active drug registrations with the Philippines FDA. As of the data cutoff (2026-04-04), the market status is Not Marketed with a total of 0 approved licenses on record. There are no product entries to display.

This represents an administrative market gap rather than a scientific one — the drug is globally approved and widely available in most comparable markets.

Safety Considerations

Please refer to the package insert for safety information. No key warnings, contraindications, or drug interaction data were retrievable from the current evidence sources for Cetirizine.

Note for review team: Safety data (TFDA/FDA-approved labeling, warnings, and contraindications) has been identified as a Blocking data gap (DG001). The Philippines NDA submission cannot proceed to Stage 1 safety assessment until the approved package insert is obtained and parsed. In addition, a recent 2025 case report (PMID 41602253) flagged rebound pruritus/urticaria upon long-term cetirizine discontinuation in Asian patients — this should be captured in the local risk management plan.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Cetirizine’s efficacy for allergic urticaria is mechanistically well-founded and globally validated by FDA and EMA approvals. The Philippines market gap is regulatory in nature — not a signal of insufficient evidence — and can be addressed through standard new drug application pathways using international reference dossiers.

To proceed, the following is needed:

Resolve Blocking Safety Gap (DG001): Download and parse the TFDA/FDA/EMA-approved package insert PDF to extract full warnings, contraindications, and drug interaction data before entering Stage 1 safety assessment
Confirm MOA documentation (DG002): Query DrugBank API (DB00341) to formally document mechanism of action for inclusion in regulatory and formulary submissions
File Philippines FDA registration: Submit NDA or abbreviated NDA leveraging existing FDA/EMA approval as reference product; Cetirizine’s established international safety profile should support an expedited review pathway
Develop rebound urticaria risk communication: Based on the 2025 case report (PMID 41602253), prepare patient counseling materials specifically addressing discontinuation risk in chronic urticaria patients on long-term therapy — particularly relevant for the Asian patient population
Establish local post-marketing surveillance plan in line with Philippines FDA pharmacovigilance requirements
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.